Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC

被引：0
|
作者：
Peyrin-Biroulet, L. [1 ]
Yen, M. [2 ]
Zhou, W. [2 ]
Dong, B. [2 ]
Danese, S. [3 ]
Feagan, B. G. [4 ,5 ]
Sands, B. E. [6 ]
机构：
[1] CHRU Nancy, INFINY Inst, Dept Gastroenterol, INSERM,NGERE, Nancy, France
[2] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Gastroenterol & Gastrointestinal Endoscopy Unit, Milan, Italy
[4] Western Univ, Dept Med Epidemiol, London, ON, Canada
[5] Western Univ, Dept Biostat, London, ON, Canada
[6] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1259
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1085
引用
收藏
页码：i1997 / i1998
页数：2
相关论文
共 42 条
  • [21] Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies
    D'Haens, Geert
    Baert, Filip
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward V.
    Sandborn, William J.
    Dornic, Quentin
    Lindner, Dirk
    Kisfalvi, Krisztina
    Marins, Ed G.
    Vermeire, Severine
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (04) : 404 - 415
  • [22] Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study
    Panaccione, Remo
    Bossuyt, Peter
    Blumenstein, Irina
    Biedermann, Luc
    Torres, Joana
    Vladea, Ramona
    Cheng, Ling
    Zhang, Yafei
    Kalabic, Jasmina
    Chien, Karen
    Morisset, Pierre
    Parkes, Gareth
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1060 - S1060
  • [23] Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
    Hisamatsu, Tadakazu
    Peyrin-Biroulet, Laurent
    Dignass, Axel
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Houck, Nicole
    Miao, Ye
    Zhang, Hongyan
    Argollo, Marjorie
    Takeuchi, Ken
    Filip, Rafal
    Allegretti, Jessica R.
    Feagan, Brian G.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S810 - S810
  • [24] Treatment benefits of upadacitinib based on disease severity, disease duration and number of prior biologics in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 3 trial data
    Loftus, Edward, Jr.
    Torres, Joana
    Parkes, Gareth
    Takeuchi, Ken
    Xuan, Si
    Crooks, James
    Klaff, Justin
    Gonzalez, Yuri Sanchez
    Gilmore, Robert
    Danese, Silvio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 169 - 169
  • [25] EARLY CHANGE IN CDAI PREDICTS IMPROVED QUALITY OF LIFE AFTER 12-WEEK INDUCTION THERAPY WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: A POST HOC ANALYSIS FROM APOLLO-CD
    Siegel, Corey A.
    Kharrat, Houssam A.
    Yen, Mark
    Lu, J. D.
    Luo, Allison
    DuVall, Aaron
    GASTROENTEROLOGY, 2024, 166 (05) : S806 - S806
  • [26] UPADACITINIB MONOTHERAPY IMPROVES PATIENT-REPORTED OUTCOMES IN METHOTREXATE-NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM SELECT-EARLY
    Strand, Vibeke
    Tundia, Namita
    Radominski, Sebastiao
    Friedman, Alan
    Dunlap, Kendall
    Goldschmidt, Deborah
    Bergman, Martin
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 372 - 373
  • [27] C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2
    Dubinsky, Marla C.
    Hudesman, David
    Steinwurz, Flavio
    Kulisek, Nicole
    Salese, Leonardo
    Paulissen, Jerome
    Su, Chinyu
    de Leon, Dario Ponce
    Magro, Fernando
    GASTROENTEROLOGY, 2020, 158 (06) : S1196 - S1197
  • [28] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE Study
    Pascual, J.
    Buse, D. C.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Pichard, H.
    Klatt, J.
    Mikol, D.
    HEADACHE, 2018, 58 : 179 - 180
  • [29] Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine Patients with Prior Prophylactic Treatment Failure: Results from a Post-Hoc Analysis of the STRIVE study
    Pascual, J.
    Buse, D.
    Starling, A. J.
    Ailani, J.
    Zhang, F.
    Wen, S.
    Bilitou, A.
    Desai, P.
    Picard, H.
    Klatt, J.
    Mikol, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 409 - 409
  • [30] Mirikizumab Demonstrates Sustained Improvement in Fatigue in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Regueiro, Miguel
    Gibble, Theresa Hunter
    Bleakman, Alison Potts
    Li, Xingyuan
    Morris, Nathan
    Eastman, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S518 - S519
12345